Retention and excretion of inhaled 3H and 14C radiolabeled methane in rats.

A radiological concern for workers at heavy water reactor nuclear facilities is the hazard presented by tritium (H) and C. Radioactive methane is one of many potential H and C containing chemicals to which Nuclear Energy Workers (NEWs) may be exposed. Current dosimetric models for H- and C-methane, recommended by the International Commission on Radiological Protection (ICRP), are based on the assumption that 1% of methane is absorbed following its inhalation. Of this 1%, all H is converted immediately to tritiated water and C is converted immediately to CO2 (50%) and organically bound carbon (50%). In the study, rats were exposed to methane standards (H-methane and C-methane) mixed with breathing air to give a final concentration of 0.27% methane and resulting in final activity concentrations of 4.2 GBq m and 0.88 GBq m for H and C, respectively. This corresponds to exposure estimates of 580 kBq g and 120 kBq g. Simultaneous exposure to H- and C-methane allowed for the direct comparison of the retention of these radionuclides and removed uncertainties concerning their relative uptake and retention. The results demonstrate that the total methane uptake from the inhaled dose was threefold less than the 1% methane uptake predicted by the ICRP dosimetric models for H- and C-methane, with the H concentration being substantially higher than anticipated in the liver. This study provided data suggesting that current ICRP dosimetric methane models overestimate the fraction of H- and C-methane that is absorbed following inhalation and assisted in providing information to better understand the metabolism of inhaled H and C radiolabeled methane.

Retention and excretion of ³H in rats following the intratracheal intubation of tritiated pump oil.

Saturated hydrocarbon mineral oils in vacuum pumps used in ³H handling facilities often contain significant amounts of ³H (as much as several hundred GBq L⁻¹), and during maintenance the air around an open pump may contain MBq L of volatile and aerosol species. It follows that H-contaminated pump oils pose a workplace hazard-especially if inhaled deposits are retained in the lung. A long-term study (1-y duration) was undertaken to establish the retention time of ³H-pump oil in the lungs of rats. Excretion data was collected to establish the mechanism of oil clearance from the lung. Finally, liver data was collected both to indicate the levels of H in the rat body and to indicate either the presence or absence of the transfer of unmetabolized pump oil within cells from the lungs to liver. Within 1 d following intubation into the trachea, ∼16.5% of the emulsified pump oil had been rapidly mechanically cleared to feces, and 1.1%, present as HTO, or exchangeable H, was excreted in urine. 69.4% of the instilled dose remained in the lungs as the initial alveolar burden. Subsequently, H cleared from the lungs with a retention half-time of of 223 d. The lung burden was mostly cleared to feces-indicating that the pump oil droplets remaining in the lungs were behaving like insoluble particles, but the kinetics of clearance of particles and oil droplets may be different. Overall, it is concluded that inhaled H-pump oil should most likely be regarded as an insoluble particulate (ICRP Inhalation Type S) for the purposes of radiological protection dosimetry, but the possibility of Type M behavior cannot be excluded.

Cancer and non-cancer risks in normal and cancer-prone Trp53 heterozygous mice exposed to high-dose radiation.

This report tests the hypotheses that cancer proneness elevates risk from a high radiation exposure and that the risk response to high doses is qualitatively similar to that from low doses. Groups of about 170 female mice heterozygous for Trp53 (Trp53(+/-)) and their normal female littermates (Trp53(+/+)) were exposed at 7-8 weeks of age to (60)Co gamma-radiation doses of 0, 1, 2, 3 or 4 Gy at a high dose rate (0.5 Gy/min) or 4 Gy at a low dose rate (0.5 mGy/min). In the absence of radiation exposure, Trp53 heterozygosity reduced life span approximately equally for death from either cancer or non-cancer disease. Heterozygosity alone produced a 1.5-fold greater shortening of life span than a 4-Gy acute exposure. Per unit dose, life shortening from cancer or non-cancer disease was the same for normal mice and Trp53 heterozygous animals, indicating that, contrary to previous reports, Trp53 heterozygosity did not confer radiation sensitivity to high doses of gamma rays. In Trp53(+/-) mice with cancer, life shortening from acute doses up to 4 Gy was related to both increased tumor formation and decreased tumor latency. A similar tumor response was observed in normal mice, but only up to 2 Gy, indicating that above 2 Gy, normal Trp53 function protected against tumor initiation, and further life shortening reflected only decreased latency for cancer and non-cancer disease. Dose-rate reduction factors were 1.7-3.0 for both genotypes and all end points. We conclude that Trp53 gene function influences both cancer and non-cancer mortality in unexposed female mice and that Trp53-associated cancer proneness in vivo is not correlated with elevated radiation risk. Increased risk from high acute radiation doses contrasts with the decreased risk seen previously after low doses of radiation in both Trp53 normal and heterozygous female mice.

A lower dose threshold for the in vivo protective adaptive response to radiation. Tumorigenesis in chronically exposed normal and Trp53 heterozygous C57BL/6 mice.

Low doses of ionizing radiation to cells and animals may induce adaptive responses that reduce the risk of cancer. However, there are upper dose thresholds above which these protective adaptive responses do not occur. We have now tested the hypothesis that there are similar lower dose thresholds that must be exceeded to induce protective effects in vivo. We examined the effects of low-dose/low-dose-rate fractionated exposures on cancer formation in Trp53 normal or cancer-prone Trp53 heterozygous female C57BL/6 mice. Beginning at 6 weeks of age, mice were exposed 5 days/week to single daily doses (0.33 mGy, 0.7 mGy/h) totaling 48, 97 or 146 mGy over 30, 60 or 90 weeks. The exposures for shorter times (up to 60 weeks) appeared to be below the level necessary to induce overall protective adaptive responses in Trp53 normal mice, and detrimental effects (shortened life span, increased frequency) evident for only specific tumor types (B- and T-cell lymphomas) were produced. Only when the exposures were continued for 90 weeks did the dose become sufficient to induce protective adaptive responses, balancing the detrimental effects for these specific cancers and reducing the risk level back to that of the unexposed animals. Detrimental effects were not seen for other tumor types, and a protective effect was seen for sarcomas after 60 weeks of exposure, which was then lost when the exposure continued for 90 weeks. As shown previously for the upper dose threshold for protection by low doses, the lower dose boundary between protection and harm was influenced by Trp53 functionality. Neither protection nor harm was observed in exposed Trp53 heterozygous mice, indicating that reduced Trp53 function raises the lower dose/ dose-rate threshold for both detrimental and protective tumorigenic effects.

Fractionated, low-dose-rate ionizing radiation exposure and chronic ulcerative dermatitis in normal and Trp53 heterozygous C57BL/6 mice.

The influence of low-dose-rate chronic radiation exposure and adaptive responses on non-cancer diseases is largely unknown. We examined the effect of low-dose/low-dose-rate fractionated or single exposures on spontaneous chronic ulcerative dermatitis in Trp53 normal or heterozygous female C57BL/6 mice. From 6 weeks of age, mice were exposed 5 days/week to single daily doses (0.33 mGy, 0.7 mGy/h) totaling 48, 97 or 146 mGy over 30, 60 or 90 weeks, and other Trp53+/- mice were exposed to a single dose of 10 mGy (0.5 mGy/min) at 20 weeks of age. The 90-week exposure produced an adaptive response, decreasing both disease frequency and severity in Trp53+/+ mice and extending the life span of older animals euthanized due to severe disease. The 30- or 60-week exposures had no significant protective or detrimental effect. In contrast, the chronic, fractionated exposure for 30 or 60 weeks significantly increased the frequency and severity of the disease in older Trp53+/- mice, significantly decreasing the life span of the animals required to be euthanized for disease. Similarly, the single 10-mGy exposure also increased disease frequency in older animals. However, the chronic, fractionated exposure for 90 weeks prevented these detrimental effects, with disease frequency and severity not different from unexposed controls. We conclude that very low-dose fractionated exposures can induce a protective adaptive response in both Trp53 normal and heterozygous mice, but that a lower threshold level of exposure, similar in both cases, must first be passed. In mice with reduced Trp53 functionality, doses below the threshold can produce detrimental effects.